-+ 0.00%
-+ 0.00%
-+ 0.00%

Kangfang Biotech initially rose 5.8%, then narrowed its gains. Earlier, the company announced that compared to Mercadon's pabolizumab, its tumor immunization drug evosil significantly extended the median overall survival period to 30.8 months, compared to 22.6 months for the former.

Zhitongcaijing·09/14/2026 02:17:14
Listen to the news
Kangfang Biotech initially rose 5.8%, then narrowed its gains. Earlier, the company announced that compared to Mercadon's pabolizumab, its tumor immunization drug evosil significantly extended the median overall survival period to 30.8 months, compared to 22.6 months for the former.